Aeterna Zentaris Slides on Perifosine Miss in Myeloma
By Staff Reports
Shares of Aeterna Zentaris dropped 22.5 percent Monday after a data safety monitoring board (DSMB) said it was unlikely a Phase III study testing PI3/Akt inhibitor perifosine in multiple myeloma would hit its endpoints.
